What Oystershell laboratories does

Oystershell Laboratories is a Belgium-headquartered consumer health product developer founded in 1979 that pivoted from its original oyster-shell calcium supply business to self-medication and dermatology products following a 2002 management buyout led by bioengineer Bart Rossel. The company operates two units: Oystershell Consumer Health, which markets four own brands (RID in the USA, Elimax, Pistal, Nvive, and Ultractive) in lice treatment, insect protection, digestive health, and women's wellness; and Oystershell Laboratories, a B2B contract-development business that develops product innovations for more than 30 leading consumer healthcare companies and licenses finished-product IP to be commercialized under customer-owned brands in over 80 countries.

The technology backbone rests on a portfolio of patented proprietary platforms rather than a single dominant product: the LiquiShell delivery format (a chewable shell with a liquid core that enables fast absorption and high liquid loading, applied across OTC and VMS), the LPF (Licensed Protection Factor) lice-protection technology used in Elimax, the ClearWick anti-clog wick in Pistal diffusers, and a cryogenic device technology positioned as the world's first safe at-home wart treatment that achieves lower temperatures than traditional propane/ether devices. These innovations are paired with a #1 market position in lice treatment in the USA and a #1 position in cryogenic wart treatment globally, supported by a regulatory dossier depth that yields 3–4 year development cycles for new medical devices.

The business model is asset-light: manufacturing is outsourced to contract producers overseen by Oystershell's supply chain team, while R&D, regulatory, quality, IP, and brand marketing are retained in-house. Revenue is generated through three streams — own-brand product sales via distributors, online pharmacies, Amazon, and an Ultractive webshop in core territories (Belgium, USA, Austria, Portugal); licensing royalties and finished-product supply agreements with 30+ healthcare customers; and managed-services supply chain oversight. The company has been majority-owned by private equity firm Rivean Capital (formerly Gilde) since a 2017 controlling-stake acquisition.

Name

Oystershell laboratories

Legal name

Oystershell

Website

http://www.oystershell.com/en

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

11–50 employees

Short description

Oystershell Laboratories is a Belgian consumer health company that develops and markets innovative self-medication products through two units: own-brand Consumer Health (RID, Elimax, Pistal, Nvive, Ultractive) and a B2B Laboratories arm licensing 30+ product innovations to healthcare companies across 80+ countries.

Ownership category

akta.pro rank

Product category

Consumer Healthcare

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Multivitamins & Daily Packs (CRADAGAC)

akta.pro secondary industries

Probiotics & Digestive Health Supplements (CRADAGAF), Vitamins & Minerals (Single Nutrients) (CRADAGAB), Specialty & Functional Packaged Foods (Gluten-Free, Keto, Organic, Medical/Allergen-Friendly) (CRADAAAI), OTC & Consumer Health Distributors (HLAIAJAC)

Keywords

• Consumer healthcare products
• Lice treatment products
• Dermatology treatments
• Nutritional supplements
• Private label manufacturing

Headquarters

HQ city

Drongen

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Own Brand Product Sales: Oystershell Consumer Health markets four category-leading brands (RID, Elimax, Pistal, Nvive) in core territories (USA, Belgium, Austria, Portugal). Revenue generated from direct sales of consumer health products through distributors, online pharmacies, Amazon, and own webshop.
2. Licensing and Supply Agreements: Oystershell Laboratories develops product innovations for third-party healthcare companies. New product developments result in agreements on licensing out the IP and supplying finished products to customers. Over 30 long-term healthcare company customers commercialize products under their own brands in over 80 countries.
3. Contract Manufacturing Oversight: Asset-light model combining own know-how and technologies with outsourced manufacturing. Best-in-class contract manufacturers produce products, overseen by Oystershell's supply chain team.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Oystershell Laboratories develops and markets innovative consumer healthcare products across dermatology, lice and insect treatment, and nutritional supplements. The company operates two units: Consumer Health markets its own brands (RID, Elimax, Pistal, Nvive, Ultractive) directly to consumers through pharmacies, online pharmacies, Amazon, and its own webshop, while Laboratories develops product innovations, licenses IP, and supplies finished products to more than 30 third-party healthcare companies commercializing under their own brands in over 80 countries.

Product overview

Oystershell Laboratories is a consumer health company operating two distinct business units: Oystershell Consumer Health markets four category-leading brands (RID, Elimax, Pistal, Nvive) in lice treatment, insect protection, and digestive health, while Oystershell Laboratories develops and licenses innovative products (lice treatments, wart treatments, nail fungus treatments, wound healing) to third-party healthcare companies. The company owns the proprietary LiquiShell technology platform, a center-filled gummy delivery format combining liquid cores with chewable shells, which is used in Nvive and available for licensing to partners. Products are marketed in over 80 countries through both Oystershell's own brands and customer-owned brands under licensing agreements.

Differentiator

Problem solved

Functional benefit

Brands

• RID: America's #1 Lice Brand Equity. Products include RID Super Max (pesticide-free lice treatment), RID Pure Power (100% natural lice treatment), and RID Daily Defense (everyday shampoo and conditioner for lice defense).
• Elimax
• Pistal
• Ultractive
• Nvive
• LiquiShell

Products and services

• RID America's #1 lice treatment brand featuring pesticide-free formulations. The product line includes RID Super Max (a 5-in-1 complete kit with 24/7 lice defense), RID Pure Power (first 100% natural lice treatment effective against super lice and eggs), and RID Daily Defense (gentle everyday shampoo and conditioner providing 24/7 lice defense). Targeted at US consumers and families needing OTC lice treatment.
• Elimax Lice treatment brand using world-leading technology that is 100% effective against lice and nits without insecticides or silicones. Features patented LPF technology that protects against re-infestation for up to 3 days. Includes Elimax Natural Lotion based on exclusively natural ingredients. Targeted at European consumers and families needing OTC lice treatment.
• Pistal Insect and microorganism protection brand based on plant-based ingredients with proven efficacy. Product range includes insect sprays, the Pistal Mosquito plug-in diffuser with ClearWick technology, and Pistal Air Purifier. Targeted at consumers seeking natural, plant-based insect protection for families.
• Nvive First LiquiShell-powered product under Oystershell's own brand. Nvive is a liquid-filled gummy combining a liquid ginger core with a chewable outer shell for rapid relief from digestive discomfort, travel-related nausea, and mild indigestion, using highly concentrated gingerol extract. Targeted at Belgian consumers seeking fast-acting digestive support.
• Ultractive Women's wellness nutritional supplement brand offering benefits from stress relief to improved memory. Products include Ultractive Magnesium, Lights Out sleep aid, and Multi Boost vitality and resistance supplement. Distribution is online-first via online pharmacies and the Ultractive webshop, targeting women in Belgium seeking stress relief, better sleep, memory support, and vitality.
• LiquiShell Proprietary oral dosage delivery format featuring a chewable shell with a liquid core. Merges benefits of liquid and solid dosage forms, enabling fast absorption, protection of heat-sensitive actives, and unusually high liquid loading. Fully customizable in flavor, color, and ingredients. Vegan and supports both OTC and VMS (vitamins, minerals, supplements) applications. Available for licensing to healthcare companies.
• Oystershell Laboratories Contract Development and Licensing B2B contract development service for third-party healthcare companies. Oystershell develops product innovations, licenses IP, and supplies finished products under customer-owned brands. Portfolio includes lice treatments, cryogenic wart treatments, nail fungus treatments, and wound healing products marketed in over 80 countries through 30+ long-term healthcare company customers.

Quantifiable outcome

• 100% effective lice and nit elimination with single 5-minute treatment
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Contract ManufacturerscoreOthersLong-term partnerships with best-in-class contract manufacturers for the production of products. Oystershell outsources production which is overseen by their supply chain team. Oystershell manages and pays contractors while retaining all intellectual property and patents.
• Consumer Healthcare CompaniescoreStrategic or Co-development PartnerOver 30 leading consumer healthcare companies partner with Oystershell Laboratories for product innovation. These customers commercialize Oystershell's product innovations under their own brands through licensing and supply agreements. Products are marketed in over 80 countries.
• Distributors and Service ProvidersminorChannel Partner/ Reseller/ DistributorLocal distributors and service providers implement marketing, sales and logistics strategy for Consumer Health products in core territories (USA, Belgium, Austria, Portugal).
• Nerdland PodcastminorGTM or Marketing PartnerSponsored Nerdland podcast episodes to reach science-curious audiences. CEO Bart Rossel appeared on podcast and co-authored book 'How Do You Make That?' featured on the show.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Haleon: Spun out of GSK as a pure-play consumer health company spanning OTC, oral care and vitamins. Highly comparable as a global consumer-health brand owner serving pharmacy and retail channels, though much larger and broader than Oystershell.
• Church & Dwight: US-listed consumer health and household products company with a portfolio of category-leading brands sold through mass and pharmacy channels. Comparable as a multi-brand OTC/consumer health operator and as the former owner of the RID brand that Oystershell acquired in 2020.
• Perrigo Company: Specializes in OTC self-care products and store-brand (private label) consumer healthcare, including through its Omega Pharma subsidiary in Europe. Comparable business model of OTC development plus distribution across European pharmacy channels, similar to Oystershell's licensing-plus-own-brand approach.
• Bayer Consumer Health: Division of Bayer focused on OTC and consumer health products across dermatology, pain, and nutrition in global markets. Comparable as a global consumer health brand owner in OTC and self-care categories where Oystershell competes with own brands and licenses innovations to partners.
• Reckitt Benckiser: Global consumer health and hygiene company behind brands like Nurofen, Gaviscon and Durex. Comparable as a global OTC brand owner with strong pharmacy and retail presence and active M&A history in consumer health.
• SC Johnson: Global consumer products company with a leading insect repellent portfolio (e.g. OFF!). Comparable as a competitor in the consumer insect-protection category where Oystershell's Pistal brand operates, though SC Johnson is far larger and broader in scope.

Direct peers

• Prestige Consumer Healthcare: US-listed acquirer and marketer of OTC consumer healthcare brands across categories including personal care and dermatology. Highly comparable as a roll-up operator of niche OTC brands — similar strategic logic to Oystershell's own-brand-plus-licensing model.
• HRA Pharma (Perrigo): European OTC specialist in women's health, dermatology and self-care, now part of Perrigo. Comparable in focus on niche OTC product development and licensing across European pharmacy channels, similar to Oystershell Laboratories' B2B innovation model.
• Omega Pharma (Perrigo): Belgian-based OTC and personal care company now owned by Perrigo. Direct regional peer given shared Belgian HQ region and European pharmacy-channel distribution model used by Oystershell's own-brand business.
• Almirall: European specialty pharmaceutical company focused on dermatology and self-care. Comparable as a Europe-based developer and marketer of dermatology/OTC products, overlapping with Oystershell's Elimax and Pistal categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInbe.linkedin.com/company/oystershell-nv

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oystershell laboratories